AnGes MG,Inc. AnGes MG,Inc. Japanese Site
Home News Releases About Us Projects For Investors
Print
  News Releases
  The latest news
  Back numbers
HOME > News Releases > The latest news
News Releases The latest news

List
Back numbers >>Back numbers
2009  
December 25 Issuance of Notice of Termination of the License Agreement with Transcription Factor Therapeutics, LLC, on NF-κB Decoy
November 24 Agreement on SPA with the US FDA for Phase III Clinical Trial for CollategeneTM, a Drug for Ischemic Disease Treatment
November 24 Product Patent on Dumbbell-Type (Ribbon-Type) E2F Decoy Oligonucleotide Granted in Japan
--- Covering a Circular Oligonucleotide Sequence ---
October 22 Patent on New Decoy Oligonucleotide Granted in Japan
—Covering NF-κB/ets chimera (double) decoy—
September 3 AnGes MG Project Adopted by NEDO as Next Generation Strategic Business Program
– Development of Drug-Eluting PTA Balloon Catheter –
August 31 Project of AnGes MG Subsidiary GenomIdea Adopted as Strategic Basic Technology Sophistication Supportive Program - R&D of New Method for Biopharmaceuticals Manufacturing Using Technology to Maintain Vacuum -
July 29 Medical-Use Patent on NF-κB Decoy Oligonucleotide Granted in Japan - Covering Psoriasis -
July 14 AnGes Project Selected by R&D Project for Creation of Regional Innovation -Development of Medical Products Based on Functional Peptides Derived from Plant Regeneration Mechanism-
April 27 Joint R&D with Morishita Jintan Co., Ltd.-Development of New Products Based on Functional Peptides with Antimicrobial Activity-
April 15 Substance Patent on Dumbbell-Type (Ribbon-Type) NF-κB Decoy Oligonucleotide Granted in Japan -Covering a Circular Oligonucleotide Sequence-
March 26 AnGes Project Adopted to Receive NEDO Support
- Development of Novel Disinfectants with Antibacterial Peptides -
March 2 AnGes Reached a Broad Agreement with the FDA on the Clinical Trial Designs for Their Phase III Study with Collategene™
February 16 Announcement about the progress of Allovectin-7® Phase 3 pivotal trial
February 6 AnGes MG continues the collaborations of plasmid HGF for Japan market with Daiichi-Sankyo while the US/Europe marketing rights are returned
February 4 Efficacy of NF-κB decoy oligodeoxynucleotides for periodontal disease confirmed in an animal study -An academic paper published in the scientific journal, Antioxidants & Redox Signaling-
February 2 GenomIdea, a Subsidiary of AnGes MG, Signs a Licensing Contract for GEN0101

Back numbers >>Back numbers
Page Top


Copyright 2004 AnGes MG All rights reserved. Contact | Site Map | Site Policy | Privacy Policy